Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

8.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
8.0K
Tumor Progression02:07

Tumor Progression

3.6K
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High species discrimination in <i>Pedicularis</i> (Orobanchaceae): Plastid genomes and traditional barcodes equally effective via parsimony-informative sites.

Plant diversity·2026
Same author

Solvent-mediated construction of phosphate/carboxyl bifunctional hyper-cross-linked polymers for highly efficient uranium removal from aqueous solutions.

Journal of hazardous materials·2026
Same author

The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses.

Communications biology·2025
Same author

Heterologous expression of the M. abscessus CBASS system confers phage TM4 resistance in M. smegmatis.

BMC microbiology·2025
Same author

Prediction of outcomes following intravenous thrombolysis in patients with acute ischemic stroke using serum UCH-L1, S100β, and NSE: a multicenter prospective cohort study employing machine learning methods.

Therapeutic advances in neurological disorders·2025
Same author

Achieving Improved Buried Interface Enabled by Oriented Bridging Molecules in Near-Infrared Perovskite Light-Emitting Diodes.

ACS applied materials & interfaces·2025

Related Experiment Video

Updated: Apr 15, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.2K

Recent progress in HER2 associated breast cancer.

Wei-Jia Wang1, Yuan-Yuan Lei, Jin-Hong Mei

  • 1Department of Pathology, the First Affiliated Hospital of Nanchang University, Nanchang, China E-mail : mjhdoctor@126.com; wang330006@126.com.

Asian Pacific Journal of Cancer Prevention : APJCP
|April 10, 2015
PubMed
Summary

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, common in women, grows rapidly but responds well to therapies. Research focuses on new treatments for this aggressive cancer type.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

876

Related Experiment Videos

Last Updated: Apr 15, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

876

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Breast cancer is a leading global cancer in women, with 15-23% over-expressing human epidermal growth factor receptor 2 (HER2).
  • HER2-positive breast cancer is characterized by rapid growth, poorer survival rates, and increased recurrence risk.
  • Despite challenges like drug resistance, HER2-positive tumors are a significant target for anti-cancer immunotherapy.

Purpose of the Study:

  • To review the role of HER2 in breast cancer pathogenesis.
  • To discuss current and emerging therapeutic strategies for HER2-positive breast cancer.
  • To analyze prognostic factors associated with HER2-positive breast cancer.

Main Methods:

  • Literature review of studies on HER2 in breast cancer.
  • Analysis of therapeutic modalities targeting HER2.
  • Examination of prognostic indicators in HER2-positive cases.

Main Results:

  • HER2 overexpression is linked to aggressive tumor behavior and worse prognosis.
  • HER2-positive breast cancer shows a notable response to specific adjuvant therapies.
  • Drug resistance remains a challenge, highlighting the need for novel treatment approaches.

Conclusions:

  • HER2 plays a critical role in breast cancer progression and prognosis.
  • Targeted therapies and immunotherapy offer promising treatment avenues for HER2-positive breast cancer.
  • Ongoing research into new treatments is crucial for improving outcomes and overcoming resistance.